Interim

Healthcare Triangle Breaks New Ground in AI-Powered Patient Data Management with readabl.ai

Retrieved on: 
Wednesday, April 3, 2024
Automation, FHIR, Intelligence, Electronic health record, LLM, API, HCTI, Interim, Machine learning, Triangle, Health, Health care

This collaboration establishes a revolutionary benchmark in the management and utilization of patient data, ultimately elevating the standards for enhanced care delivery.

Key Points: 
  • This collaboration establishes a revolutionary benchmark in the management and utilization of patient data, ultimately elevating the standards for enhanced care delivery.
  • By leveraging Healthcare Triangle’s expertise in artificial intelligence and machine learning, the system adeptly identifies and extracts vital data from documents, faxes, and narrative reports.
  • A hallmark of this collaboration is Healthcare Triangle’s development of an unparalleled AI model that actively learns from real-time healthcare data.
  • Key Achievements through this collaboration Include:
    Enhanced Patient Care: Improved patient data processing speed and accuracy significantly boosts the delivery of patient care.

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Zymeworks Inc. (ZYME)

Retrieved on: 
Tuesday, April 2, 2024
Interim management, Senior, Interim, SVP, Zymeworks, News, CFO, Private investigator

NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME ).

Key Points: 
  • NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME ).
  • The investigation concerns whether Zymeworks and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On April 1, 2024, Zymeworks disclosed that it had removed Christopher Astle from the positions of Senior Vice President and Chief Financial Officer, effective immediately.
  • Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.

Joshua Chandler joins D-BOX as the new Chief Financial Officer

Retrieved on: 
Tuesday, April 2, 2024
Interim, MBA, Corporation, Organization, TSX, CFA, Cook it, Growth, Management

MONTREAL, April 02, 2024 (GLOBE NEWSWIRE) -- D-BOX Technologies Inc. (“D-BOX” or the “Corporation”) (TSX:DBO), a world leader in haptic and immersive entertainment, is pleased to announce the appointment of Joshua Chandler (CFA, MBA) as Chief Financial Officer of the Corporation, effective April 22, 2024.

Key Points: 
  • MONTREAL, April 02, 2024 (GLOBE NEWSWIRE) -- D-BOX Technologies Inc. (“D-BOX” or the “Corporation”) (TSX:DBO), a world leader in haptic and immersive entertainment, is pleased to announce the appointment of Joshua Chandler (CFA, MBA) as Chief Financial Officer of the Corporation, effective April 22, 2024.
  • He will supervise the financial and operational activities of the Company.
  • “We are very happy to welcome Mr. Chandler to our executive team,” says Sébastien Mailhot, President and CEO of D-BOX.
  • Sébastien Mailhot, President and CEO of D-BOX, has been appointed as Interim Chief Financial Officer of the Corporation for the period of March 31, 2024, the effective date of resignation of the former chief financial officer of the Corporation, to April 22, 2024.

Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue

Retrieved on: 
Tuesday, April 2, 2024
MRD, Adaptation, Interim, Genetics, Investment, ADPT, CFO, Management

Management will provide further details on the process and outcome of the strategic review during the conference call this afternoon.

Key Points: 
  • Management will provide further details on the process and outcome of the strategic review during the conference call this afternoon.
  • Total revenue of approximately $41 to $43 million for the first quarter of 2024, an increase of approximately 12% compared to the first quarter of 2023.
  • MRD revenue of approximately $31 to $32 million for the first quarter of 2024, an increase of approximately 47% compared to the first quarter of 2023.
  • Adaptive Biotechnologies announced that Tycho Peterson, chief financial officer (CFO), will be departing the company to pursue another opportunity.

Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer

Retrieved on: 
Tuesday, April 2, 2024
Interim, Management

REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the appointment of Mehul Joshi as Chief Financial Officer, effective April 3, 2024.

Key Points: 
  • REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the appointment of Mehul Joshi as Chief Financial Officer, effective April 3, 2024.
  • He succeeds John McKune, who has served as the Company’s Interim Chief Financial Officer since October 10, 2023, and will transition to his prior role as Vice President, Corporate Controller.
  • "Mehul is an exceptionally accomplished financial executive and I am excited to welcome him to our leadership team.
  • "I would also like to thank John McKune for stepping into the role of Interim Chief Financial Officer and for his continued leadership on the finance team.”
    “I am thrilled to join Pulmonx as Chief Financial Officer at this exciting time for the company,” stated Mehul Joshi.

Netcoins announces unaudited Q1 2024 Results

Retrieved on: 
Tuesday, April 2, 2024
Crypto, Growth, Assets under management, SOL, Digital asset, Acquisition, Small business, United, Bank statement, ETH, Investment, CAD, OTC, Ecosystem, Interim, Cryptocurrency

VANCOUVER, British Columbia, April 02, 2024 (GLOBE NEWSWIRE) -- BIGG Digital Assets Inc. (“BIGG” or the “Company”) (CSE: BIGG; OTCQX: BBKCF; WKN: A2PS9W), a leading innovator in the digital assets space and owner of Netcoins , and Blockchain Intelligence Group and TerraZero is pleased to report Netcoins unaudited Q1 2024 results.

Key Points: 
  • VANCOUVER, British Columbia, April 02, 2024 (GLOBE NEWSWIRE) -- BIGG Digital Assets Inc. (“BIGG” or the “Company”) (CSE: BIGG; OTCQX: BBKCF; WKN: A2PS9W), a leading innovator in the digital assets space and owner of Netcoins , and Blockchain Intelligence Group and TerraZero is pleased to report Netcoins unaudited Q1 2024 results.
  • Q1 2024 Netcoins Canada Crypto Staking Highlights:
    Netcoins Staking Assets Under Management over $3.6 million ETH.
  • To celebrate the addition of these assets, Netcoins Canada will offer No Fee* Staking for both SOL and ATOM in 2024.
  • We are pleased with Netcoins’ Q1 2024 results and are focused on all of BIGG’s divisions to follow suit with expected user growth and launching of new products and services aimed at larger audiences.”
    BIGG’s unaudited consolidated interim financial statements and related management’s discussion and analysis for the three months ended March 31, 2024, will be prepared and filed on SEDAR+ within the regulatory filing timelines.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME

Retrieved on: 
Monday, April 1, 2024
CFO, SVP, Zymeworks, News, LLP, Senior, Interim management, Pomerantz, Interim

NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).

Key Points: 
  • NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).
  • 7980
    The investigation concerns whether Zymeworks and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

Retrieved on: 
Monday, April 1, 2024
Zebra, News, LLP, Bank statement, Therapy, Pomerantz, Interim, Audit committee, Audit

NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. (“Zevra” or the “Company”) (NASDAQ: ZVRA).

Key Points: 
  • NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. (“Zevra” or the “Company”) (NASDAQ: ZVRA).
  • The investigation concerns whether Zevra and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

Retrieved on: 
Monday, April 1, 2024
Research, PMN, FTLD, Biotechnology, MSA, ALS, Multiple system atrophy, CSF, Patient, Neuroscience, Epitope, Immunoglobulin G, RACK1, Cerebrospinal fluid, Activated, Synucleinopathy, Clinical trial, PROMIS, Antibody, Vaccination, Safety, Pharmacokinetics, Interim, Therapy, Blood, SAD, Frontotemporal lobar degeneration, Pharmaceutical industry

This is a very exciting opportunity for both ProMIS and the AD patients we aim to serve.

Key Points: 
  • This is a very exciting opportunity for both ProMIS and the AD patients we aim to serve.
  • ProMIS dosed the first participants in a first-in-human Phase 1a clinical trial of PMN310 as a potential treatment for AD in November 2023 (Study NCT06105528 ).
  • Using a proprietary computational platform, ProMIS identified potential conformational epitopes (misfolded portions) unique to toxic alpha-synuclein involved in synucleinopathies.
  • Cash and cash equivalents were $12.6 million as of December 31, 2023, compared to $5.9 million as of December 31, 2022.

BROG 4-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Brooge Energy (BROG) Investors with Substantial Losses to Contact Firm’s Attorneys Before Apr. 5th Deadline in Securities Fraud Class Action

Retrieved on: 
Monday, April 1, 2024
BROG, SAN, Acquisition, Person, Interim, Hagens Berman

SAN FRANCISCO, April 01, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Brooge Energy Limited (NASDAQ: BROG) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, April 01, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Brooge Energy Limited (NASDAQ: BROG) investors who suffered substantial losses to submit your losses now .
  • Brooge Energy consented to a settlement with the SEC, acknowledging violations of numerous federal securities law provisions, including antifraud and reporting requirements.
  • But a recently filed securities class action suit seeks to recover additional monetary compensation for Brooge investors resulting the alleged fraud.
  • “We believe Brooge investors have not been fairly compensated for this brazen alleged fraud,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.